Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Wanbury Ltd. Share Price
Day's Range
Day's Range
Low
₹241.00
High
₹249.50
Price Summary
| Previous Close | ₹243.00 |
|---|---|
| Day's Range | ₹241.00 - ₹249.50 |
| Open | ₹248.40 |
| 52 Week Range | ₹161.50 - ₹358.85 |
| Volume | 65,816 |
| Market Cap | ₹0.00 |
| Previous Close | ₹243.40 |
|---|---|
| Day's Range | ₹241.00 - ₹249.20 |
| Open | ₹248.15 |
| 52 Week Range | ₹162.00 - ₹360.00 |
| Volume | 4,626 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 159.93 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 19.94 |
| TTM EPS (₹) | 12.29 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 12.77 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
| Trade Value ( ₹ in Lacs) | 11.26 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 19.94 |
| TTM EPS (₹) | 12.29 |
| P/E Ratio | 25.19 |
| Book Value(₹) | 12.77 |
| PAT Margin (%) | 5.06 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 35.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1631.84 | 5995.14 |
| Expenses | N/A | N/A |
| PBT | 136.06 | 295.51 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 134.9 | 305.3 |
About Wanbury Ltd.
| Founded | 1988 |
|---|---|
| NSE Symbol | WANBURY |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,63,791.45 | 1,917.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,45,080.59 | 9,230.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,351.29 | 4,930.80 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,308.33 | 8,706.30 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,16,281.31 | 673.30 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,14,832.64 | 1,136.45 | 835.50 - 835.50 |
| Cipla Ltd. | 1,14,162.52 | 1,398.00 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,00,660.17 | 1,871.00 | 823.10 - 823.10 |
| Lupin Ltd. | 98,431.05 | 2,147.00 | 1,875.00 - 1,875.00 |
| Mankind Pharma Ltd. | 98,304.73 | 2,365.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Wanbury informs about updates
Further to its letter dated 20th July, 2026, Wanbury has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in Annexure - I.
The above information is a part of company’s filings submitted to BSE.
Wanbury informs about disclosure
Wanbury informs about SAST disclosure
Dolphin Medical Services informs about AGM
Tyche Industries informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wanbury Ltd. is ₹243.00 as of 2026-09-03.
The market capitalisation of Wanbury Ltd. is ₹857.04 as of 2026-09-02.
The 1-year return of Wanbury Ltd. is -36.25% as of 2026-09-03.
The P/E ratio of Wanbury Ltd. is 25.19 as of 2026-09-03.
The 52-week high and low of Wanbury Ltd. are ₹358.85 and ₹161.50, respectively, as of 2026-09-03.
People Also Ask
Wanbury Ltd. was originally incorporated as Pearl Organics Limited in August 1988. The company adopted the name Wanbury Limited in September 2004. This change reflected its transition into a pharmaceutical manufacturing business with a broader operational scope and growing presence in domestic and international markets.
Wanbury Ltd. is a publicly listed company whose equity shares are traded on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Being listed on these exchanges allows participation from both retail and institutional investors and ensures compliance with regulatory disclosure and governance standards.
Wanbury Ltd. generates revenue through the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and pharmaceutical formulations. The company produces and exports medicines used in therapeutic areas such as diabetes management. Its operations include production, research, and distribution across multiple regulated and semi-regulated global markets.
Pradeep Patni serves as the Chief Executive Officer of Wanbury Ltd., having assumed the role in August 2024. He is responsible for overseeing the company’s strategic direction and operations, working alongside Mohan Kumar Rayana, who is the Promoter and Whole-Time Director involved in leadership and governance functions.
Wanbury Ltd. is a pharmaceutical company engaged in the development and manufacturing of APIs and formulations. With over three decades of experience, it operates integrated facilities that support research and production. The company supplies its products to domestic and international markets, including regulated regions across various therapeutic categories.
Explore More Articles About Indices
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
